Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth

AIDS Patient Care and STDs

Volumn 26, Issue 4, 2012, Pages 193-196

  Agwu, Allison L ^a   Bethel, James ^b   Hightow Weidman, Lisa B ^c   Sleasman, John W ^d   Wilson, Craig M ^e   Rudy, Bret ^f   Kapogiannis, Bill G ^g  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WESTAT   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; BIOGEOGRAPHIC REGION; CD4+ T LYMPHOCYTE; DISEASE DURATION; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RISK; JUVENILE; LETTER; NONHUMAN; PRIMARY PREVENTION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION; VIRUS TRANSMISSION;

ADOLESCENT; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENES, MDR; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; PHYLOGENY; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, VIRAL; UNSAFE SEX; YOUNG ADULT;

EID: 84859312790     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0420     Document Type: Letter

References (12)

1. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drugresistance: 2009 update. PLoS One 2009;4:e4724.
2. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010;18:156-163.
3. Viani RM, Peralta L, Aldrovandi G, et al. Prevalence of primary HIV-1 drug resistance among recently infected adolescents: A multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis 2006;194: 1505-1509. (Pubitemid 44851891)
4. Ammaranond P, Cunningham P, Oelrichs R, et al. Rates of transmission of antiretroviral drug resistant strains of HIV-1. J Clin Virol 2003;26:153-161. (Pubitemid 36206600)
5. Tossonian HK, Raffa JD, Grebely J, et al. Primary drug resistance in antiretroviral-naive injection drug users. Int J Infect Dis 2009;13:577-583.
6. Mellins CA, Tassiopoulos K, Malee K, et al. Behavioral health risks in perinatally HIV-exposed youth: Co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment. AIDS Patient Care STDs 2011;25:413-422.
7. Hightow-Weidman LB, Hurt CB, et al. Transmitted HIV-1 drug resistance among young men of color who have sex with men: A multicenter cohort analysis. J Adolesc Health 2011;48:94-99.
8. Mitsch A, Hu X, McDavid Harrison K, Durant T. Division of HIV/AIDS Prevention, National Center for HIV AIDS Viral Hepatitis STD and TB Prevention CDC. Trends in HIV/AIDS diagnoses among men who have sex with men 33 states, 2001-2006. 2008. May 17, 2010.
9. Goldsamt LA, Clatts MC, Parker MM, Colon V, Hallack R, Messina MG. Prevalence of sexually acquired antiretroviral drug resistance in a community sample of HIV-positive men who have sex with men in New York City. AIDS Patient Care STDs 2011;25:287-293.
10. Hurt CB, Matthews DD, Calabria MS, et al. Sex with older partners is associated with primary HIV infection among men who have sex with men in North Carolina. J Acquir Immune Defic Syndr 2010;54:185-190.
11. Leigh Brown AJ, Frost SD, Mathews WC, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003;187:683-686. (Pubitemid 36250034)
12. Rudy BJ, Kapogiannis BG, Lally MA, et al. Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. J Acquir Immune Defic Syndr 2010;54 Suppl 1:S31-S42.